ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2606

How to Classify Spondyloarthritis after a Two Year Follow up? Results from the French Recent onset spondyloarthritis Cohort

Pierre Gazeau1, Divi Cornec2, Marie Agnès Timsit1, Valerie Devauchelle3, Sandrine Jousse-Joulin1, Thierry Marhadour4, Emmanuel Nowak5, Maxime Dougados6 and Alain Saraux7, 1Rheumatology, CHU Brest, Brest, France, 2Department of rheumatology and unit of immunology, Brest Occidentale University, Brest, France, 3Rheumatology, Brest university medical school, EA 2216, Lab Ex, INSERM, IGO,UBO and CHU de la Cavale Blanche,, Brest, France, 4Rheumatology, CHU de la Cavale Blanche, Brest, France, 5CIC, CHU Brest, Brest, France, 6INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France., Paris, France, 7Rhumatologie, CHU Brest and EA 2216, UBO, Brest, France

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Diagnostic criteria and spondylarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Spondyloarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment III

Session Type: Abstract Submissions (ACR)

Background/Purpose:

In early arthritis, after a two years follow up, rheumatologist diagnosis of rheumatoid arthritis agrees well with 2010 ACR/EULAR criteria (Saraux A et al. Arthritis care Arthritis Res (Hoboken). 2013;65:1227-34). Today, we do not have straightforward rules to diagnose spondyloarthritis (SpA) after a two year follow up, and we do not know the gap between rheumatologist diagnosis and SpA defined using all potential methods to classify patients having inflammatory low back pain (IBP).

Methods:

We used the nationwide, longitudinal, prospective cohort (DESIR) of patients with IBP suggestive of SpA at baseline. After 2 years, patients were classified based on: imaging (MRI, X-rays), the certainty with which the rheumatologist diagnosed SpA (evaluated on 0-100 visual analogue scales), treatment used (non-steroidal anti-inflammatory drugs [NSAID] and/or TNF-alpha blockers) and classification criteria (any among axial Assessment of SpA international Society [ASAS] criteria, European SpA Study Group [ESSG] and Amor). First, we described clinical, biological and imaging characteristics, the items of all classification criteria and the diagnosis established by the rheumatologists after 2 years. Second, we evaluated the certainty in the diagnosis of SpA at inclusion and after a 2 year follow-up. Third, using ROC curves, we determined the best end point of the diagnosis certainty using the validated classification criteria (AMOR, ESSG, and ASAS) as gold standards. Then, we evaluated agreement between all potential methods to classify patients having IBP based on Cohen’s kappa coefficient in the whole group and in the group having a MRI.

Results:

On the 708 patients initially included, 548 had information on rheumatologist’s certainty after 2 years. Using ROC curves, we found that a certainty of diagnosis ≥ 75% gave the best balance of sensitivity and specificity. This certainty of diagnosis increased with the follow up [357 of 548 (65.1%) patients had a certainty≥75% after a two year follow up versus 265 (48.3%) at inclusion]. Certainty of diagnosis≥75% after a two year follow up was statistically associated with all classification criteria (AMOR p: 0.005; ESSG p: 0.003; ASAS p<0.0001) and the ASAS criteria had the best agreement, although it was low (kappa 0.09, 0.11 and 0.25 for AMOR, ESSG and ASAS, respectively). None of the various other potential classifications items had a better agreement.

Conclusion:

Rheumatologist diagnosis of SpA certainty after 2 years does not agree well with the various previously published criteria for SpA.


Disclosure:

P. Gazeau,
None;

D. Cornec,
None;

M. A. Timsit,
None;

V. Devauchelle,
None;

S. Jousse-Joulin,
None;

T. Marhadour,
None;

E. Nowak,
None;

M. Dougados,
None;

A. Saraux,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/how-to-classify-spondyloarthritis-after-a-two-year-follow-up-results-from-the-french-recent-onset-spondyloarthritis-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology